Dupixent's Quarterly Sales by Sanofi Exceed €3B for First Time

Sanofi reported a significant increase in the sales of its product Dupixent for the second quarter, with a 29.2% rise that brought revenues to €3.3 billion ($3.6 billion). This marks a new quarterly record for the medication, and the company anticipates that Dupixent will generate around €13 billion in revenue for the entire year. The treatment recently received approval in Europe for the treatment of chronic obstructive pulmonary disease (COPD), with the U.S. decision pending and expected by September 27.

Beyond Dupixent, Sanofi is banking on several new drugs and a revitalized R&D sector to drive earnings growth in the coming years. These new launches, including Altuviio, Nexviazyme, Rezurock, and Sarclisa, collectively contributed €707 million to biopharma sales in the second quarter. This accounted for 7% of the company's total biopharma sales during this period.

Sanofi's CEO, Paul Hudson, highlighted the company's robust performance, noting a broad-based, double-digit sales growth in the second quarter of 2024. Overall sales for this quarter saw a 7.8% increase, reaching €10.7 billion. However, the company's net income experienced a decline of 22.4%, dropping to €1.1 billion. Despite this dip in net income, Hudson emphasized the company's progress in its transformation efforts, which has led Sanofi to revise its earnings per share guidance for 2024. Initially predicting a decrease by a low single-digit percentage, Sanofi now expects earnings to remain stable at constant currencies.

Sanofi's ambitious plans and strategic moves highlight its focus on innovation and growth. The company’s strategy includes capitalizing on the potential of its new drugs, alongside its flagship product Dupixent, to drive future revenue and earnings. This approach is part of Sanofi's broader effort to strengthen its position in the biopharmaceutical market and ensure sustained growth in the competitive healthcare industry.